Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q7Z6Z6

UPID:
PLPL5_HUMAN

ALTERNATIVE NAMES:
GS2-like protein

ALTERNATIVE UPACC:
Q7Z6Z6; B1AHL8; B3KPR1; Q6ZST0

BACKGROUND:
The enzyme Patatin-like phospholipase domain-containing protein 5, with alternative names including GS2-like protein, exhibits abundant triacylglycerol lipase activity. This activity underscores its importance in the hydrolysis of triacylglycerols to free fatty acids, a fundamental process in the regulation of lipid levels within the organism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Patatin-like phospholipase domain-containing protein 5 holds the key to unlocking novel therapeutic avenues. Given its central role in lipid metabolism, targeting this protein could lead to innovative treatments for conditions stemming from lipid dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.